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A Systematic Review 
and Cost Analysis in the 
Australian Setting
We read with great interest the 
article by Ruben and Ball.1  The authors 
presented a systematic review and 
cost analysis of the efficacy of fluoro-
deoxyglucose (FDG)-positron emis-
sion tomography (PET) staging for 
small-cell lung cancer (SCLC) in the 
Australian setting. Their main conclu-
sion was that PET-based staging seems 
to be superior to conventional staging 
and can result in significant alterations 
to a patient’s management particu-
larly with regard to radiotherapy (RT) 
treatment.
There is no doubt that because 
of the compelling appearance of SCLC 
on FDG-PET images together with the 
evidence in non–small-cell lung cancer 
demonstrating how FDG-PET results 
influence stage and prognostic stratifica-
tion compared with conventional imag-
ing, FDG-PET imaging is an attractive 
staging tool that is slowly being inte-
grated into routine practice. However, 
we would argue that clinicians currently 
do not have sufficient evidence to sup-
port a change of therapy based on FDG-
PET in the SCLC setting.
First, we would like to emphasize 
the lack of robust evidence for the use 
of FDG-PET-based staging in chang-
ing clinical practice and the uncertainty 
about its impact on survival. Patients 
with stage IV disease or extensive dis-
ease (ED) are a heterogeneous group 
ranging from those with a solitary 
metastasis to those with a heavy burden 
of metastatic disease.
None of the phase III clinical trials 
that have established the role for concur-
rent chemoradiotherapy in the treatment 
of stage I–III or limited disease were 
performed in the era of FDG-PET and 
therefore probably included a propor-
tion of patients with metastatic disease 
not detectable by conventional imaging. 
In the era of high-definition computed 
tomography imaging, patients who are 
upstaged to ED by FDG-PET may well 
have a low burden of metastatic disease 
and the benefit of combined treatment 
with chemotherapy and RT in this set-
ting is unknown. Studies are currently 
ongoing in Europe (Chest Radiotherapy 
Extensive Stage Small Cell Lung 
Cancer [CREST]) and the United States 
(RTOG 0937), aiming to demonstrate 
the impact on survival of the addition of 
thoracic RT to prophylactic cranial irra-
diation in patients with ED.
Second, we would like to empha-
size that, unlike the studies conducted 
in non–small-cell lung cancer, the rapid 
doubling time of SCLC and the lack of 
need for precise anatomic/histologi-
cal staging to inform initial treatment 
decisions has precluded histological 
verification to validate the findings in 
FDG-PET staged patients. The sensitiv-
ity and specificity of PET-based stag-
ing (approaching 100% and exceeding 
90%, respectively) reported by Ruben 
and Ball are based on clinical or patho-
logical correlation to confirm or refute 
the imaging findings. However, as 
pointed out by the authors only half of 
the 22 studies reviewed for the purpose 
of their article used adequate criteria 
and 14 of the studies were retrospective.
Despite the absence of data cor-
relating FDG-PET staging with patho-
logical findings, RT target volumes are 
being altered as a result of FDG-PET 
imaging in the staging of the medias-
tinum. None of the published studies 
examining the impact of FDG-PET 
in altering the radiation field volume 
performed histological verification of 
the mediastinum, and the impact on 
local control when disease was treated 
by FDG-PET–defined volume has not 
been reported.2 Similarly, pathologi-
cal confirmation was not available in 
a Dutch study looking at the effect of 
omitting elective nodal irradiation on 
the basis of PET-computed tomography 
staging.3
In summary, although we agree 
with the authors that FDG-PET can 
help refine the staging of SCLC patients 
compared with conventional imag-
ing alone, the true impact of this tech-
nique on the management and survival 
of patients is unknown in a disease 
in which most patients probably have 
occult metastasis. It is therefore crucial 
that prospective studies are conduced 
to address these questions and ensure 
that patients are not denied effective 
treatment. The ongoing international 
Concurrent ONce-daily VErsus twice-
daily RadioTherapy (CONVERT) study 
(NCT00433563) comparing twice-daily 
versus once-daily RT concurrently with 
chemotherapy in limited disease-SCLC 
does not mandate FDG-PET staging, 
but data on staging investigations are 
collected. It will be of interest to investi-
gate the impact on survival of FDG-PET 
staging in patients treated with concur-
rent chemoradiotherapy.
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